• Open Access

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas

Authors


  • Disclosures Drs Pertel, Eisenstein and Martone are employees of Cubist Pharmaceuticals and own company stock and stock options. Dr Bernardo is a consultant for Cubist Pharmaceuticals. Dr Link has received honoraria for serving on the speakers bureau for Cubist Pharmaceuticals. Drs Donfrid and Biermann have no potential conflicts to report. Clinical Trials. gov number
    NCT00295178

  • Verification
    All the authors had access to the data and a role in writing the manuscript.

  • Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

Peter E. Pertel,
Clinical Research, Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA
Tel.: + 1 781 860 8577
Fax: + 1 781 860 1377
Email: peter.pertel@cubist.com

Summary

Background:  Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections.

Objective:  The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin.

Design:  The study was a prospective, evaluator-blinded, multi-centre trial. Patients were randomised to receive daptomycin 4 mg/kg once daily or vancomycin according to standard of care for 7–14 days.

Patients:  Adults diagnosed with cellulitis or erysipelas requiring hospitalisation and intravenous antibiotic therapy were eligible for enrolment.

Results:  The clinical success rates were 94.0% for daptomycin and 90.2% for vancomycin (95% confidence interval for the difference, −6.7%, 14.3%). There were no statistically significant differences between treatment arms in the time to resolution or improvement in any of the predefined clinical end-points. Both daptomycin and vancomycin were well tolerated.

Conclusions:  There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin. Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas.

Ancillary